证券代码：000756 证券简称：新华制药 公告编号：2025-46 二、审议通过关于修订《公司章程》及相关议事规则的议案（《关于修订〈公司章程〉及相关 议事规则的公告》见同日发布于巨潮资讯网公告）。 本议案尚需提交公司股东大会审议。 9 名董事赞成本议案，0 票反对，0 票弃权。 山东新华制药股份有限公司 第十一届董事会第八次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈 述或重大遗漏。 山东新华制药股份有限公司（"本公司"）第十一届董事会第八次会议通知于二零二五年八月 十二日以电邮形式发出，会议于二零二五年八月二十六日在山东省淄博市高新区鲁泰大道 1 号公 司会议室召开，应到会董事 9 名，实际参会董事 9 名。监事会成员和非董事的副总经理列席了会 议。会议由董事长贺同庆主持。会议的召开符合有关法律、法规、规章和公司章程的规定。 会议主要审议并通过了以下议案： 一、审议通过本公司 2025 年半年度报告及业绩公告（2025 年半年度报告及其摘要见同日发布 于巨潮资讯网公告）。 9 名董事赞成本议案，0 票反对，0 票弃权。 上述议案经公司股东大会审议通过后， ...

Core Viewpoint - Recently, Xinhua Pharmaceutical (000756) announced the approval of several drug registration certificates by the National Medical Products Administration, indicating a positive development for the company's product portfolio [1] Group 1 - Xinhua Pharmaceutical received the drug registration certificate for Sacubitril/Valsartan Sodium Tablets and Minoxidil Lotion [1] - The wholly-owned subsidiary, Xinda Pharmaceutical, received the drug registration certificate for Clarithromycin Dry Suspension [1]

南财智讯8月26日电，新华制药发布2025年半年度报告，报告期实现营业收入46.39亿元，同比下降 1.98%；归属上市公司股东的净利润2.24亿元，同比下降15.69%；扣除非经常性损益后的归属于上市公 司股东的净利润2.11亿元，同比下降15.44%；基本每股收益0.32元。 ...

Core Viewpoint - Xinhua Pharmaceutical has received approval from the National Medical Products Administration for the Minoxidil topical solution, which is intended for the treatment of male pattern baldness and alopecia areata [1] Group 1: Product Approval - The approval of Minoxidil topical solution enhances the product portfolio of Xinhua Pharmaceutical [1] - This product is expected to contribute to the company's competitiveness in the market [1] Group 2: Market Potential - The estimated sales revenue for Minoxidil in Chinese public medical institutions is approximately RMB 2.36 billion in 2024 [1] - The approval aligns with the growing demand for treatments related to hair loss in the healthcare sector [1]

新华制药公告，2025年上半年营业收入46.39亿元，同比下降1.98%。净利润2.24亿元，同比下降 15.69%。公司计划不派发现金红利，不送红股，不以公积金转增股本。 ...

Financial Performance - The company's operating revenue for the reporting period was approximately CNY 4.64 billion, a decrease of 1.98% compared to the same period last year[12]. - Total profit for the period was CNY 263.53 million, reflecting a decline of 13.13% year-over-year[12]. - Net profit attributable to shareholders was CNY 223.76 million, down 15.69% from the previous year[12]. - The net profit after deducting non-recurring gains and losses was CNY 210.86 million, a decrease of 15.44% year-over-year[12]. - The company reported a basic earnings per share of CNY 0.32, down 17.95% from the same period last year[12]. - Operating profit for the current period is RMB 264.25 million, down 13.06% from RMB 307.57 million in the previous period[118]. - Total comprehensive income for the current period is RMB 245.71 million, compared to RMB 300.09 million in the previous period, reflecting a decrease of 18.14%[118]. Cash Flow and Liquidity - The net cash flow from operating activities increased significantly by 202.49%, reaching CNY 234.13 million[12]. - The company's cash flow from operating activities demonstrates the company's ability to generate cash from its core business operations, which is crucial for future growth[120]. - The net cash flow from operating activities for the current period is RMB 234,132,352.73, an increase of 40.3% compared to RMB 77,401,054.87 in the previous period[120]. - The ending balance of cash and cash equivalents is RMB 1,163,830,264.02, up from RMB 850,921,699.35 in the previous period[120]. - The company's liquidity ratios showed a current ratio of 126.64% and a quick ratio of 87.66% as of June 30, 2025[67]. Shareholder Information - As of June 30, 2025, the total number of shareholders is 76,508, including 40 H-share shareholders and 76,468 A-share shareholders[20]. - The top three shareholders hold the following shares: 204,864,092 shares (29.70%) by Hualu Holdings Group Co., Ltd., 193,314,037 shares (28.03%) by Hong Kong Central Clearing (Agent) Co., Ltd., and 37,091,988 shares (5.38%) by Hualu Investment Development Co., Ltd.[21]. - The company plans not to distribute dividends for the first half of 2025[8]. - The board of directors has proposed not to distribute dividends for the first half of 2025, maintaining the previous year's dividend of RMB 0.025 per share[76]. Assets and Liabilities - Total assets at the end of the reporting period amounted to CNY 9.24 billion, an increase of 2.42% compared to the end of the previous year[12]. - The company's total liabilities rose to CNY 3.87 billion, marking a 1.86% increase from the previous year[12]. - The asset-liability ratio stood at 41.92%, indicating a stable financial structure[71]. - Total current assets reached RMB 3,992,086,651.00, an increase of 22.5% from RMB 3,726,840,162.91 at the end of the previous year[114]. Research and Development - Research and development investment decreased by 12.56% to approximately ¥202.78 million from ¥231.91 million in the previous year[56]. - The company has over 100 products in the research and development pipeline, supported by multiple R&D platforms[74]. - The company aims to secure over 10 new product approvals for APIs and formulations in the second half of the year[44]. Employee Information - The company reported a total of 7,159 employees, with 2,043 holding a university degree or higher[33][34]. - The company conducted 38 training sessions in the first half of 2025, with 2,281 participants, enhancing training effectiveness[35]. - The number of shares held by directors and senior management increased to 2,870,150 shares as of June 30, 2025, from 2,055,050 shares on January 1, 2025[26]. Market and Product Development - A total of 10 new formulation products were launched in the first half of the year, with 19 products and 25 specifications winning national procurement bids[38]. - The company plans to develop three key markets in South America and two potential markets in the Middle East and Africa, focusing on specialty APIs like L-DOPA and fish oil series[43]. - The company achieved export revenue of $152.475 million, indicating exposure to foreign exchange risk[72]. Corporate Governance and Compliance - The company has adhered to corporate governance codes and has not deviated from the rules set by the Hong Kong Stock Exchange[108]. - The audit committee has reviewed the financial accounting principles and methods for the six months ending June 30, 2025, and has agreed with the disclosures made[109]. - There were no significant lawsuits or arbitration matters during the reporting period[4]. Financial Management and Accounting - The company's financial statements are prepared in accordance with the accounting standards issued by the Ministry of Finance and relevant regulations[136]. - The group recognizes significant bad debt provisions for receivables exceeding RMB 5 million[139]. - The group assesses credit risk for receivables based on aging, nature of the receivables, and historical collection data, grouping them by similar credit risk characteristics[178].

Core Viewpoint - Shandong Xinhua Pharmaceutical has received approval from the National Medical Products Administration for the registration of Minoxidil lotion, which is expected to enhance the company's product portfolio and overall competitiveness [1] Company Summary - The Minoxidil lotion was approved for registration in August 2025, indicating a future expansion in the company's product offerings [1] - This approval is anticipated to strengthen the company's market position and competitive edge in the pharmaceutical industry [1]

Core Viewpoint - Shandong Xinhua Pharmaceutical has received approval from the National Medical Products Administration for the marketing of Sacubitril/Valsartan tablets, which are indicated for the treatment of chronic heart failure and hypertension, enhancing the company's competitive edge in cardiovascular disease treatment [1] Group 1: Product Approval and Indications - The product, Sacubitril/Valsartan tablets, is approved for adult patients with reduced ejection fraction chronic heart failure (NYHA II-IV, LVEF ≤ 40%), aimed at reducing cardiovascular mortality and hospitalizations due to heart failure [1] - The tablets can replace ACE inhibitors or ARBs and can be used in combination with other heart failure medications [1] - Additionally, the product is indicated for the treatment of primary hypertension [1] Group 2: Market Potential and Financial Impact - Sacubitril/Valsartan tablets are classified as a Category B drug in the National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug Catalog (2025) [1] - The estimated sales revenue for Sacubitril/Valsartan tablets in Chinese public medical institutions is approximately RMB 4.9 billion in 2024 [1] - The approval of this product is expected to enrich the company's portfolio in cardiovascular treatments and enhance its overall competitive advantage [1]

Core Viewpoint - Shandong Xinhua Pharmaceutical Co., Ltd. has received approval for the registration of Clarithromycin suspension, which is expected to enhance the company's product offerings in the anti-infection drug category and improve its overall competitiveness [1][2]. Group 1: Product Approval - The company's wholly-owned subsidiary, Shandong Zibo Xinda Pharmaceutical Co., Ltd., has been granted a drug registration certificate for Clarithromycin suspension by the National Medical Products Administration [1]. - The application for the marketing authorization of Clarithromycin suspension was submitted in December 2023 and was accepted, with the registration certificate obtained in August 2025 [1]. Group 2: Indications and Market Potential - Clarithromycin is indicated for treating infections caused by pathogens sensitive to it, including upper respiratory infections, lower respiratory infections, skin and soft tissue infections, and acute otitis media [2]. - The estimated sales revenue for Clarithromycin in public medical institutions in China is approximately RMB 1.123 billion in 2024 [2]. - The approval of Clarithromycin suspension will enrich the company's anti-infection drug portfolio [2].

Core Viewpoint - Shandong Xinhua Pharmaceutical Co., Ltd. has received approval from the National Medical Products Administration for the drug registration certificate of Sacubitril/Valsartan tablets, indicating a significant advancement in its product portfolio for treating heart failure and hypertension [1] Group 1: Product Approval - The company has been granted a drug registration certificate for Sacubitril/Valsartan tablets, which are indicated for adult patients with heart failure with reduced ejection fraction (NYHA class II-IV, LVEF ≤ 40%) [1] - This medication aims to reduce the risk of cardiovascular death and hospitalization due to heart failure [1] - Sacubitril/Valsartan tablets can replace ACE inhibitors or ARBs and can be used in combination with other heart failure treatments [1] Group 2: Therapeutic Applications - In addition to heart failure, Sacubitril/Valsartan tablets are also indicated for the treatment of primary hypertension [1]